OptimizeRx Corporation (OPRX)
After hours:
| Previous close | 10.70 |
| Open | 10.94 |
| Bid | 10.56 x 100 |
| Ask | 10.65 x 100 |
| Day's range | 10.60 - 10.97 |
| 52-week range | 6.92 - 16.65 |
| Volume | |
| Avg. volume | 133,851 |
| Market cap | 193.113M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Insider Monkey
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript March 28, 2024 OptimizeRx Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2023 Conference Call. With us today is […]
